Device/Diagnostics Quarterly Deal Statistics, Q2 2016
A look at financing, M&A and alliance activity April–June 2016
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
You may also be interested in...
HeartWare has found a way to pay for the expanded commercialization of its HVAD ventricular assist device and the development of its MVAD miniaturized ventricular assist device; the Boston-area VAD-maker has agreed be acquired by medtech giant Medtronic for $1.1bn in cash.
The $1 billion acquisition of the maker of the Mobi-C cervical disc replacement is expected to put Zimmer Biomet in a better position in the spine device market.
Medtronic is putting its sales and marketing power behind Israel-based Mazor Robotics with new commercial agreement and investment deals, both announced May 18.